Q4 2025 Evolent Health Inc Earnings Call Transcript
Key Points
- Evolent Health Inc (EVH) reported strong Q4 results, with revenue and adjusted EBITDA landing in the upper half of their guidance range.
- The company is experiencing significant growth in its oncology segment, which is expected to account for approximately 65% of revenue in 2026, up from 36% in 2025.
- Evolent Health Inc (EVH) successfully renegotiated contracts to the enhanced performance suite model, covering approximately 90% of performance suite revenue.
- The company has secured major new contracts, including a large oncology partnership with Highmark, expected to contribute significantly to 2026 revenue.
- Evolent Health Inc (EVH) is aggressively pursuing cost efficiencies through AI and automation, exceeding their $20 million Q4 2025 annualized savings target.
- The company faces a temporary headwind in 2026 due to exchange membership declines, impacting revenue by approximately $100 million.
- Evolent Health Inc (EVH) anticipates a higher medical expense ratio (MER) in 2026, expected to be around 93% compared to 89% in 2025.
- The new contracts are expected to create a temporary headwind to 2026 adjusted EBITDA due to conservative reserving methodologies.
- There is a significant impact from the 'one big beautiful bill,' resulting in a $40 million headwind to specialty TNS revenue.
- The company is experiencing churn in its administrative services business, notably due to a customer acquisition by a large national plan.
(audio in progress) As a reminder, this conference call is being recorded -- and Mario Ramos, Chief Financial Officer.
This call will be archived and available later this evening and for the next week via the webcast on the company's website in the US federal laws. These statements are subject to risks purely from historical experience or present expectations. A description of some of these that are filed with the securities and exchange commissions, including cautionary statements including in our current the company's results and Outlook, please refer to our 3rd quarter press release issued earlier today. Finally, as a reminder, reconciliations of not the most directly comparable GAAP measures are available in the section of our website or in the company's press release issued today and posted in the investors site irr.tevvent.com and the form 8k filed by the company with the SEC earlier today.
In addition to reconciliation for the quarter in both our press release and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
